TABLE 1.

Demographic and clinical characteristics of the study subjects

	All Subjects (N = 204)	Disease Duration ≤ 10 (N = 128)	Disease Duration >10 (N = 76)	P
Age, yrs	40.52 (11.8)	36.46 (10.91)	47.35 (9.98)	P < 0.001
Gender (%)
Male	59 (28.9%)	41 (32.0%)	18 (23.7%)	0.207
Female	145 (71.1%)	87 (68.0%)	58 (76.3%)
Disease duration, yrs	9.80 (9.40)	4.03 (3.02)	19.53 (8.43)	P < 0.001
Education, yrs	14.41 (2.5)	14.08 (2.51)	14.99 (2.39)	0.013
Expanded disability status scale	2.527 (1.81)	2.14 (1.55)	3.17 (2.03)	P < 0.001
Median (IQR)	2 (2)	2 (1.5)	2.5 (3.5)	P < 0.001
Retinal nerve fiber layer, μm	82.22 (10.85)	84.98 (10.06)	77.58 (10.62)	P < 0.001
Ganglion cell inner plexiform layer, μm	74.27 (10.37)	76.93 (10.01)	68.79 (8.95)	P < 0.001
Global cognitive score	95.32 (12.32)	96.49 (11.44)	93.36 (13.52)	0.079
Memory	96.20 (13.5)	96.4 (12.74)	95.87 (14.77)	0.787
Executive function	95.61 (13.87)	97.4 (12.73)	92.59 (15.21)	0.016
Visual spatial	100.32 (16.31)	100.77 (15.31)	99.56 (17.95)	0.612
Verbal function	93.84 (20.22)	93.92 (19.82)	93.68 (21.03)	0.937
Attention	94.66 (15.29)	96.64 (12.27)	91.36 (18.96)	0.032
Information processing speed	94.67 (17.07)	95.72 (17.15)	92.85 (16.89)	0.259
Motor skills	93.15 (19.66)	95.47 (18.45)	89.17 (21.12)	0.030
Immunomodulatory treatment
Treated (%)	104 (50.9%)	68 (53.1%)	36 (47.4%)	0.432
Treatment duration, months	31.31 (44.97)	18.37 (21.35)	55.74 (64.34)	P < 0.001
Treatment type (% of patients treated)
Dimethyl fumarate	26 (25%)	22 (32.3%)	4 (11.1%)	0.018
Interferon beta	25 (24%)	16 (23.5%)	9 (25%)	0.865
Fingolimod	20 (19.2%)	9 (13.2%)	11 (30.5%)	0.522
Natalizumab	14 (13.5%)	10 (14.7%)	4 (11.1%)	0.034
Teriflunomide	12 (11.5%)	11 (16.2%)	1 (2.7%)	0.041
Intravenous immunoglobulin	5 (4.8%)	3 (4.4%)	2 (5.5%)	0.803
Ocrelizumab	2 (1.9%)	0 (0%)	2 (5.5%)	0.052

Data are presented as a mean (SD) unless otherwise specified.